Eli Lilly And Company

This early-stage study tested an oral drug called orforglipron in 120 adults with obesity or overweight (but without diabetes). The goal was to see how it changes body fat compared to a placebo over about 8 months. Researchers measured fat around organs, appetite, and weight. Thi…

This study tests whether a daily pill called orforglipron can help people with obesity or overweight maintain the weight they lost using injectable medications like tirzepatide (Zepbound) or semaglutide (Wegovy). About 376 participants who completed a prior weight-loss trial will…

This study tested a once-daily pill called orforglipron against insulin glargine in nearly 2,750 adults with type 2 diabetes, obesity or overweight, and increased cardiovascular risk. The main goal was to see if orforglipron could reduce major heart events like heart attacks or s…

This study tested baricitinib, an anti-inflammatory pill, in 784 adults with severe or very severe alopecia areata, a condition causing extensive hair loss. Participants received either baricitinib or a placebo for up to 52 weeks. The main goal was to see if baricitinib could reg…

This early-stage study tested an oral drug called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check safety and side effects, while also measuring how the drug moves through the body and affects blood sugar. Participants took the drug or a placebo for up to 1…

This completed Phase 1 trial tested an oral drug called LY3502970 in 72 healthy overweight and obese adults. The main goal was to check safety and how the body handles the drug. Participants took the drug by mouth and were monitored for up to 42 days. Results will help decide if …

This large Phase 3 trial tested a once-weekly injection called retatrutide in over 2,300 adults with obesity or overweight, including those with knee osteoarthritis or sleep apnea. The study measured weight loss and improvements in related health issues over about 89 weeks. Resul…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This completed phase 3b study tested whether tirzepatide is better than semaglutide for weight loss in 751 adults with obesity or overweight and related health problems like high blood pressure. Participants received injections of one drug or the other for about 74 weeks. The mai…

This Phase 3 trial tested baricitinib, an immune-calming pill, in 606 adults with severe or very severe alopecia areata (an autoimmune condition causing hair loss). Participants received either baricitinib or a placebo daily for 36 weeks. The main goal was to see if baricitinib c…

This study tested whether retatrutide, a medication being studied for weight loss, can help preserve kidney function in 146 adults who are overweight or obese and have chronic kidney disease (with or without type 2 diabetes). Participants received the drug or a placebo for about …

This early-stage study tested the safety of combining two drugs, abemaciclib and darolutamide, in 10 men with advanced prostate cancer that had spread and stopped responding to standard hormone therapy. The main goal was to see if the combination was safe and tolerable. Participa…

This study looked at whether starting tirzepatide, a once-weekly injection for type 2 diabetes, before Ramadan helps people manage their blood sugar safely while fasting. 166 adults with uncontrolled diabetes who planned to fast took part. Researchers measured changes in blood su…

This study tested the safety of Lyumjev, a rapid-acting insulin, in 150 adults with type 2 diabetes in India. Participants used Lyumjev along with their usual long-acting insulin for 26 weeks. The main goal was to see how many people had low blood sugar episodes. The study is alr…

This phase 3 study tested a once-daily oral medication called orforglipron against a placebo in 1613 adults with obesity or overweight and type 2 diabetes. The goal was to see if the drug helps with weight loss and improves blood sugar control. The study lasted about 77 weeks and…

This phase 2 trial tested an oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The study compared the drug to a placebo to see if it could reduce skin symptoms. Results will help determine if larger studies are warranted.

This study tested an experimental oral drug called LY3871801 in 164 adults with moderately-to-severe rheumatoid arthritis. Participants received either the drug or a placebo to see if it reduces joint swelling and pain. The trial is now complete, and results will show if the drug…

This completed Phase 1 study tested an experimental drug called LY3437943 against a placebo in 85 people with obesity. Participants were under calorie restriction, and researchers measured how the drug affected calorie intake, energy metabolism, and appetite over up to 6 months. …

This study tested the long-term safety and effectiveness of lebrikizumab, a drug for moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants who had already taken the drug in earlier studies were followed for up to 33 months. The goal was to see how well the drug c…

This study tested a once-daily pill called orforglipron in 559 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. The pill was compared to a placebo (a dummy pill) over about 54 weeks to see if it safely lowers blood sugar levels. Th…

This study tested a drug called LY3372689 in 327 people with early-stage Alzheimer's disease. The goal was to see if it is safe and can slow down memory and thinking problems. Participants took the drug or a placebo, and researchers measured changes in their daily function and co…

This study tested a drug called mirikizumab in 63 children aged 2 to 17 with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal was to see if the drug can help control the disease and improve symptoms over 52 weeks. Participants had alr…

This large Phase 3 study tested an experimental drug called remternetug in over 1,600 people with early symptoms of Alzheimer's disease. The main goal was to see if the drug could safely clear amyloid plaques from the brain, a hallmark of Alzheimer's. Participants received either…

This study tested a new drug called Mazdutide to help adults with obesity or overweight lose weight. 179 participants took either the drug or a placebo for about 62 weeks. The main goal was to see how much weight they lost after 32 weeks, with a focus on safety and effectiveness.

This study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…

This study looked at whether adding a second drug (mibavademab) to the weight-loss medication tirzepatide helps adults with obesity lose more weight than tirzepatide alone. About 392 participants with a BMI between 30 and 40 took part. The goal was to measure changes in body weig…

This study tested a medication called tirzepatide in children and teenagers aged 10 to 17 with type 2 diabetes. Participants were already taking metformin or insulin but still had high blood sugar. The goal was to see if tirzepatide could safely lower blood sugar levels better th…

This study tested a new weekly medicine called retatrutide in 537 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either the medicine or a placebo for about 11 months. The goal was to see if retatrutide safel…

This study tested whether mirikizumab can help people with moderate to severe ulcerative colitis stay in remission (symptom-free) after they had already responded to an initial treatment. About 1,300 adults who completed a prior induction study were randomly assigned to receive m…

This study tested a drug called donanemab (LY3002813) in 272 people with early symptoms of Alzheimer's disease. The goal was to see if the drug is safe and can slow down memory loss and daily functioning problems. Participants received either the drug or a placebo, and researcher…

This study tested an oral drug called LOXO-305 in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma whose cancer had returned or not responded to prior therapies. The main goal was to see how many patients had their tumors sh…

This early-stage study tested whether adding a new drug (LY3841136) to an existing weight-loss medication (tirzepatide) is safe and tolerable. 96 healthy overweight or obese adults took part over about 42 weeks. The main goal was to check for side effects, not to prove weight los…

This study tested a drug called lebrikizumab in 86 adults and teens with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve their skin condition. Researchers measured how many participants achieved at least a 75% im…

This study looked at how a new medicine, LY3209590, is processed in the bodies of 15 children with type 2 diabetes. Each child received one dose, and researchers measured the drug levels in their blood over time. The goal was to understand how the drug is absorbed and removed, no…

This study tested a drug called ramucirumab, given with standard chemotherapy, for children and young adults with a rare cancer called desmoplastic small round cell tumor (DSRCT) that had come back or not responded to treatment. The goal was to see if the combination could slow t…

This early-phase study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage, hormone-receptor-positive breast cancer. The goal was to see if the drug is safe and how it affects cancer cells before the participants had surgery. The study lasted up to 2.5 …

This study tested a once-daily pill called orforglipron in 546 adults with type 2 diabetes whose blood sugar was not well controlled despite using insulin (with or without other diabetes medications). The goal was to see if adding orforglipron could safely lower blood sugar level…

This early-stage study tested a new daily pill called LY3549492 in 36 Chinese adults with type 2 diabetes. The main goal was to check safety and side effects over about 18 weeks. Participants had diabetes for at least 6 months and were on diet, exercise, or stable metformin. This…

This study tested a once-daily medication called LY3549492 to help adults with obesity or overweight lose weight. About 288 participants took either the drug or a placebo for around one year. The main goal was to see how much weight they lost and how safe the treatment was.

This early-stage study tested a single dose of the investigational drug eloralintide in 30 Chinese adults who are overweight or have obesity. The main goal was to check safety and side effects, and to measure how the drug moves through the body. Participants were randomly assigne…

This study tested whether adding a weight-loss drug (tirzepatide) to a standard arthritis drug (ixekizumab) helps people with psoriatic arthritis who are overweight or obese. 279 adults with active psoriatic arthritis and a BMI of 27 or higher took part. The goal was to see if th…

This study tested a weekly medicine called tirzepatide to help people with obesity or overweight keep weight off after losing it. About 441 adults took part. The goal was to see if the drug helps maintain weight loss better than a placebo.

This early-phase study tested an experimental drug called LY3537982 in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goal was to measure how the drug moves through the body and to check its safety. Researchers also looked for sig…

This study tested a connected insulin management platform in 36 people with type 1 or type 2 diabetes who use insulin. The goal was to see if the platform helped them take their insulin doses on time and keep their blood sugar in a healthy range. Participants used a continuous gl…

This study tested the drug mirikizumab in 172 adults with moderate-to-severe ulcerative colitis who still had bowel urgency despite other treatments. The main goal was to see if the drug reduces the sudden, urgent need to use the bathroom. Participants were followed for 36 weeks …

This study tested a new once-daily pill, orforglipron, against another daily pill (oral semaglutide) in adults with type 2 diabetes whose blood sugar was not well controlled by metformin alone. About 1,700 participants took one of the two pills for roughly 61 weeks. The main goal…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…

This study tested a new medicine called tirzepatide in 206 Chinese adults with type 2 diabetes. Participants received either the drug or a placebo to see if it safely lowers blood sugar levels. The goal was to measure how well the drug controls diabetes over time.

This study tested a drug called lebrikizumab in 90 adults and teens with moderate-to-severe eczema who have skin of color. The goal was to see if the drug safely improves eczema symptoms, like redness and itching, over 24 weeks. Researchers measured how many participants had at l…

This study tested a new drug (LY2157299) alone or combined with standard chemotherapy (lomustine) in 158 adults with recurrent glioblastoma, an aggressive brain cancer. The goal was to see if the new drug could help patients live longer or slow tumor growth compared to chemothera…

This study tested a new once-daily pill called orforglipron against an existing drug, dapagliflozin, in adults with type 2 diabetes whose blood sugar was not well controlled with metformin alone. About 962 participants took either orforglipron or dapagliflozin for roughly 46 week…

This phase 3 study tested a weekly injection called retatrutide in 445 people who are overweight or have obesity and also have knee osteoarthritis. The goal was to see if it reduces knee pain and helps with weight loss. Participants received either the drug or a placebo for about…

This early-stage study tested two drugs, eloralintide and tirzepatide, in 188 adults with overweight or obesity. The goal was to check safety, side effects, and how the drugs move through the body. Participants received weekly injections under the skin for up to 26 weeks. Results…

This early-stage study tested a new drug called LY3532226 in 132 people with obesity to see if it is safe and how the body processes it. Participants received weekly or monthly doses, and researchers monitored side effects and drug levels in the blood. The goal was to gather safe…

This early-stage study tested a new oral drug, LY3549492, in 92 Japanese adults—some with type 2 diabetes and some healthy. The main goal was to see if the drug is safe and what side effects it might cause. Researchers also measured how much drug gets into the blood and how the b…

This study tested the safety of a new drug called LY3841136, given alone or with another drug (tirzepatide), in 128 Japanese adults who are obese or overweight. Researchers monitored side effects and how the body processes the drugs over several months. The goal was to see if the…

This completed Phase 1 study tested two different ways to give the drug remternetug: an auto-injector and a prefilled syringe. 72 healthy volunteers received a single injection to see how much drug gets into the blood and how fast the body clears it. The goal was to compare the t…

This completed Phase 1 study looked at how a single dose of selpercatinib, a cancer drug, changes the amount of rosuvastatin (a cholesterol drug) in the blood. 28 healthy Caucasian adults took part. The goal was to see if there is a drug interaction and to check safety. Results w…

This early-stage trial tested the safety of a new drug called LY3451838 in 53 healthy adults. Researchers gave the drug either into a vein or under the skin to see how the body handles it and whether it causes side effects. Since participants were healthy, the study was not desig…

This early-phase study tested the safety and tolerability of a new drug called LY3876602 in 74 healthy adults. Researchers gave single or multiple doses to see how the body processes the drug and how long it stays in the blood and spinal fluid. The goal was not to treat any disea…

This completed phase 1 study looked at how the antifungal drug fluconazole changes the way the body handles the experimental cancer drug olomorasib. Fifteen healthy volunteers took olomorasib alone and then with fluconazole, and researchers measured drug levels in their blood. Th…

This completed Phase 1 trial in 82 healthy women of non-childbearing potential looked at how food and other drugs (omeprazole, itraconazole, carbamazepine, and midazolam) affect the levels of the experimental drug LY3484356 in the blood. The goal was to understand how the body ab…

This study looked at how the drug quinidine changes the amount of orforglipron in the blood of 27 healthy adults. Participants took both drugs by mouth, and researchers measured drug levels over time. The goal was to understand how the body processes these drugs together, not to …

This study looks at how a new drug called LY4065967 is absorbed, broken down, and removed from the body in 16 healthy men. Participants will take the drug and provide blood, urine, and stool samples over about two months. The goal is to understand the drug's journey through the b…

This completed Phase 1 study looked at how imlunestrant, an oral drug, enters the bloodstream and leaves the body in women with impaired liver function compared to healthy women. 27 female participants took a single dose, and researchers measured drug levels over time. The goal w…

This completed Phase 1 study in 16 healthy adults looked at whether taking multiple doses of selpercatinib (a cancer drug) changes how the body processes repaglinide (a diabetes medication). Participants received both drugs in a fixed order, and researchers measured drug levels i…

This completed Phase 1 study tested the drug LY4268989 (MORF-057) in 144 healthy volunteers, including Japanese and Chinese participants. The goal was to measure how the body absorbs and processes the drug, its safety, and how food or other drugs like midazolam affect it. No trea…

This early-phase study tested a drug called LY4064809 in 10 healthy Chinese adults. The main goal was to see how much of the drug gets into the blood and how fast the body gets rid of it. Researchers also checked for safety and side effects. The study lasted about 21 days and the…

This completed Phase 1 study enrolled 20 healthy adults to see how a high-fat meal and the acid-reducing drug omeprazole affect how the body absorbs selpercatinib, a cancer medication. Participants took selpercatinib under different conditions (with food, without food, and after …

This study tested several new versions of insulin lispro in 54 healthy adults to see how quickly the body absorbs and removes them, and whether they cause any side effects. The goal was to gather safety and drug-level information, not to treat a disease. The study lasted up to 10…

This study looked at how the drug LY3537031 moves through the body in people with different levels of kidney function. It included 31 adults with normal kidneys, kidney impairment, or end-stage kidney disease. The goal was to measure drug levels in the blood and how long it takes…

This study looked at how the drug LY3502970 behaves in people with healthy kidneys compared to those with kidney problems. Researchers measured how much drug gets into the blood and how fast the body clears it. The goal is to understand if kidney impairment changes drug levels, w…

This study tested how quickly a new drug, LY3502970, gets into the blood and how long it stays there when given as different tablet forms compared to a capsule. It involved 26 healthy adults and lasted about 6 months. The goal was to gather safety and drug-level information, not …

This early-stage study tested the safety and side effects of a new drug called LY3985863 in 24 healthy Chinese adults. Participants received multiple doses under the skin or a placebo, and researchers monitored for any adverse events. The goal was to see how the body processes th…

This study tested a new drug called LY3522348 in 65 healthy people to see if it is safe and what side effects it might cause. Researchers also checked how the drug enters the blood and how long the body takes to get rid of it. The study had two parts, lasting up to about 6 to 8 w…

This early-stage study looked at how a single dose of the experimental drug LY3526318 changes blood flow in the skin of healthy women. Sixteen participants received the drug or a placebo, and their skin blood flow was measured after applying a cinnamon-like substance. The goal wa…

This study looked at how the body absorbs, breaks down, and gets rid of a drug called LY3502970. Ten healthy adults took the drug by mouth and also received a radioactive version through a vein. The goal was to measure how much of the oral dose reaches the bloodstream. This is a …

This study looked at how two different versions of the drug LY3502970 behave in the body. Thirty-nine healthy adults took part to help researchers measure drug levels in the blood and check for any safety issues. The goal was to gather information, not to treat a disease.

This study tested how healthy adults absorb different forms of bimagrumab, given alone or together with tirzepatide. The goal was to compare the body's concentration of these drugs, not to treat any disease. 125 healthy participants took part, and the study lasted about 4.5 month…

This completed Phase 1 study looked at how orforglipron, an experimental drug, changes the way the body processes several common medications (digoxin, simvastatin, rosuvastatin, acetaminophen, and midazolam) in 50 healthy overweight or obese adults. The goal was to measure drug l…

This study looked at how two common drugs, itraconazole and rifampin, change the way the body processes selpercatinib, a cancer treatment. Twenty-four healthy adults took part to help researchers understand these interactions. The goal was to gather safety and drug-level informat…

This study tested a new drug called LY3502970 in 34 healthy adults to see how the body absorbs and processes it after eating or fasting. Researchers took blood samples to measure drug levels and checked for any side effects. The goal was to gather safety and dosing information, n…

This study looked at how the body processes a drug called LY4064809. Seven healthy adults received the drug by mouth and by IV to compare how much enters the bloodstream. The goal was to understand the drug's absorption, not to treat any disease. Participants stayed at a research…

This study looked at how a single dose of the drug LY3502970, tagged with a tiny amount of radioactivity, is absorbed and removed from the body. Six healthy men took one dose, and researchers measured the drug and its breakdown products in blood, urine, and stool over up to 8 wee…

This study looked at how the drug LY3502970 moves through the body in people with different levels of liver function. 29 adults with healthy livers or mild, moderate, or severe liver impairment received a single dose. Researchers measured drug levels in the blood to understand ho…

This study looked at how a drug called imlunestrant affects the way the body processes other medications in healthy women who cannot become pregnant. Researchers measured how imlunestrant changed the levels of several common drugs, including repaglinide, omeprazole, dextromethorp…

This early-stage study looked at how the experimental drug LY3526318 enters and leaves the body in 16 healthy adults. Participants took either a single dose or multiple doses by mouth. The goal was to check safety and how the body processes the drug, not to treat any disease.

This study looked at how the antibiotic clarithromycin changes the amount of LY3502970 in the blood of 26 healthy adults. Participants took LY3502970 alone and then with clarithromycin to see if there is a drug interaction. The study was completed and lasted about 85 days per per…

This early-stage study tested the safety and tolerability of a new drug called LY4060874 in 121 healthy adults. Participants were monitored for side effects and how the drug moved through their bodies. The study did not aim to treat any disease, but to gather important safety inf…

This study looked at how the drug olomorasib moves through the body of 120 healthy adults. Participants took the drug by mouth and stayed overnight at the research center for 10 nights over about 7 weeks. The goal was to measure drug levels in the blood, not to treat any disease.

This study looked at how two different capsule forms of the drug olomorasib are absorbed into the blood, and whether food changes that absorption. It involved 191 healthy Japanese participants over about 6 weeks. The goal was to gather information, not to treat any disease.

This study looked at how the drug LY3537982 moves through the body in people with different levels of kidney function. Researchers compared 32 participants with normal kidneys to those with moderate or severe kidney problems. The goal was to find the right dose for people with ki…

This study looked at how the drug cyclosporine changes the amount of an experimental drug (LY3502970) in the blood of 32 healthy adults. Participants took LY3502970 alone and then with cyclosporine to compare drug levels and check for side effects. The goal was to gather safety a…

This study looked at how the drug olomorasib enters the blood and how long it takes the body to remove it in people with mild, moderate, or severe liver problems compared to healthy people. 46 adults took a single dose and were monitored for up to 6 weeks. The goal was to underst…

This study looked at how a drug called LY3484356 enters the bloodstream and leaves the body. Sixteen healthy women who cannot become pregnant took a single dose with a radioactive tracer. Researchers measured the drug in blood, urine, and stool to understand its breakdown and eli…

This study looked at how two different versions of the drug LY4064809 enter the bloodstream and how long the body takes to remove them. It involved 24 healthy adults who stayed at a research center for about a month. The goal was to gather information, not to treat any disease.

This study looked at how the body handles the drug selpercatinib in people with different levels of kidney function. 37 adults, some with kidney problems and some healthy, took a single dose. Researchers measured drug levels in the blood and urine to see if kidney impairment chan…

This study looked at whether a single dose of the cancer drug Selpercatinib changes the heart's electrical activity (QT interval) in 32 healthy adults. Participants received the drug, a placebo, or a positive control in random order. The goal was to check for heart rhythm side ef…

This study tested the safety and side effects of a single dose of lebrikizumab (given as a shot under the skin) compared to a placebo in 24 healthy Chinese adults. Researchers also measured how fast the drug enters the blood and how long the body takes to remove it. The study did…

This study looked at how taking imlunestrant multiple times changes the way the body handles midazolam, a drug used to measure liver enzyme activity. Twenty healthy women who cannot become pregnant took part. The goal was to understand drug interactions and safety, not to treat a…

This study looked at how the drug selpercatinib changes the way the body handles midazolam, a common sedative. Sixteen healthy adults took both drugs, and researchers measured drug levels in the blood. The goal was to gather safety and interaction data, not to treat any disease.

This early-stage study tested whether a new drug called LY3985297 is safe and well-tolerated in 140 healthy adults. Participants received either a single dose or multiple doses of the drug through an IV or injection under the skin. The study also measured how much drug gets into …

This study looked at how well two different autoinjectors deliver the drug mirikizumab into the bloodstream of healthy people. About 500 healthy adults received a single injection under the skin using either a standard 1-mL autoinjector or a newer 2-mL version. The goal was to se…